nodes	percent_of_prediction	percent_of_DWPC	metapath
Dimetindene—Clomipramine—GSTP1—Parkinson's disease	0.00515	0.035	CrCbGaD
Dimetindene—Chlorphenamine—SLC6A3—Parkinson's disease	0.00491	0.0334	CrCbGaD
Dimetindene—CHRM2—GPCRs, Other—DRD3—Parkinson's disease	0.00481	0.00564	CbGpPWpGaD
Dimetindene—Mepyramine—CYP2D6—Parkinson's disease	0.0048	0.0327	CrCbGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—GPR37—Parkinson's disease	0.00474	0.00555	CbGpPWpGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—MAOA—Parkinson's disease	0.00457	0.00535	CbGpPWpGaD
Dimetindene—Tripelennamine—CYP2D6—Parkinson's disease	0.00444	0.0302	CrCbGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—BDNF—Parkinson's disease	0.00441	0.00516	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Other—HTR7—Parkinson's disease	0.00435	0.0051	CbGpPWpGaD
Dimetindene—Carbinoxamine—CYP2E1—Parkinson's disease	0.00414	0.0281	CrCbGaD
Dimetindene—CHRM2—Regulation of Actin Cytoskeleton—FGF20—Parkinson's disease	0.00412	0.00483	CbGpPWpGaD
Dimetindene—KCNH2—Neuronal System—CHRNA4—Parkinson's disease	0.0041	0.00481	CbGpPWpGaD
Dimetindene—CHRM2—G alpha (i) signalling events—GRM4—Parkinson's disease	0.00405	0.00475	CbGpPWpGaD
Dimetindene—Cyclobenzaprine—HTR2A—Parkinson's disease	0.00404	0.0275	CrCbGaD
Dimetindene—HRH1—G alpha (q) signalling events—GRM5—Parkinson's disease	0.00398	0.00467	CbGpPWpGaD
Dimetindene—Chlorprothixene—DRD3—Parkinson's disease	0.00395	0.0269	CrCbGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—NGF—Parkinson's disease	0.00391	0.00458	CbGpPWpGaD
Dimetindene—Chlorprothixene—DRD1—Parkinson's disease	0.00388	0.0264	CrCbGaD
Dimetindene—CHRM2—G alpha (i) signalling events—PENK—Parkinson's disease	0.00384	0.0045	CbGpPWpGaD
Dimetindene—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—Parkinson's disease	0.00384	0.0045	CbGpPWpGaD
Dimetindene—KCNH2—Neuronal System—HSPA8—Parkinson's disease	0.00376	0.00441	CbGpPWpGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—HTR2A—Parkinson's disease	0.00372	0.00436	CbGpPWpGaD
Dimetindene—Cyclobenzaprine—CYP2D6—Parkinson's disease	0.00369	0.0251	CrCbGaD
Dimetindene—HRH1—GPCR ligand binding—GPR37—Parkinson's disease	0.00367	0.0043	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—GPR37—Parkinson's disease	0.00361	0.00423	CbGpPWpGaD
Dimetindene—Brompheniramine—CYP2E1—Parkinson's disease	0.00358	0.0244	CrCbGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM5—Parkinson's disease	0.00356	0.00418	CbGpPWpGaD
Dimetindene—KCNH2—Neuronal System—DLG4—Parkinson's disease	0.00353	0.00413	CbGpPWpGaD
Dimetindene—CHRM2—G alpha (i) signalling events—PDYN—Parkinson's disease	0.00351	0.00412	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—CHRNA4—Parkinson's disease	0.00347	0.00407	CbGpPWpGaD
Dimetindene—KCNH2—Neuronal System—GRIN2B—Parkinson's disease	0.00345	0.00404	CbGpPWpGaD
Dimetindene—KCNH2—Neuronal System—SLC6A3—Parkinson's disease	0.0034	0.00398	CbGpPWpGaD
Dimetindene—Trimipramine—SLC6A3—Parkinson's disease	0.0034	0.0231	CrCbGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—HTR1A—Parkinson's disease	0.00334	0.00392	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—TAC1—Parkinson's disease	0.00329	0.00386	CbGpPWpGaD
Dimetindene—Nortriptyline—HTR1A—Parkinson's disease	0.00316	0.0215	CrCbGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—PENK—Parkinson's disease	0.0031	0.00364	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—PENK—Parkinson's disease	0.00305	0.00358	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Other—HTR2A—Parkinson's disease	0.00305	0.00357	CbGpPWpGaD
Dimetindene—Carbinoxamine—CYP2D6—Parkinson's disease	0.00304	0.0207	CrCbGaD
Dimetindene—Promazine—DRD1—Parkinson's disease	0.00303	0.0206	CrCbGaD
Dimetindene—Trimipramine—HTR1A—Parkinson's disease	0.00297	0.0202	CrCbGaD
Dimetindene—HRH1—G alpha (q) signalling events—TAC1—Parkinson's disease	0.00289	0.00339	CbGpPWpGaD
Dimetindene—KCNH2—Neuronal System—COMT—Parkinson's disease	0.00289	0.00339	CbGpPWpGaD
Dimetindene—Imipramine—HTR7—Parkinson's disease	0.00288	0.0196	CrCbGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—TH—Parkinson's disease	0.00288	0.00337	CbGpPWpGaD
Dimetindene—KCNH2—Neuronal System—MAOA—Parkinson's disease	0.00287	0.00336	CbGpPWpGaD
Dimetindene—Amitriptyline—HTR7—Parkinson's disease	0.00286	0.0195	CrCbGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.00284	0.00333	CbGpPWpGaD
Dimetindene—Doxepin—HTR1A—Parkinson's disease	0.00283	0.0193	CrCbGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.00279	0.00327	CbGpPWpGaD
Dimetindene—Chlorprothixene—DRD2—Parkinson's disease	0.00273	0.0186	CrCbGaD
Dimetindene—Amitriptyline—DRD3—Parkinson's disease	0.00269	0.0183	CrCbGaD
Dimetindene—Nortriptyline—DRD2—Parkinson's disease	0.00268	0.0182	CrCbGaD
Dimetindene—Brompheniramine—CYP2D6—Parkinson's disease	0.00263	0.0179	CrCbGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	0.00262	0.00307	CbGpPWpGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—Parkinson's disease	0.00259	0.00303	CbGpPWpGaD
Dimetindene—Chlorphenamine—CYP2D6—Parkinson's disease	0.00258	0.0176	CrCbGaD
Dimetindene—Nortriptyline—CYP2E1—Parkinson's disease	0.00258	0.0176	CrCbGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	0.00258	0.00302	CbGpPWpGaD
Dimetindene—HRH1—G alpha (q) signalling events—ADRBK1—Parkinson's disease	0.00257	0.00301	CbGpPWpGaD
Dimetindene—Trimipramine—DRD2—Parkinson's disease	0.00253	0.0172	CrCbGaD
Dimetindene—Imipramine—SLC6A3—Parkinson's disease	0.00252	0.0171	CrCbGaD
Dimetindene—HRH1—GPCR ligand binding—GRM4—Parkinson's disease	0.00249	0.00292	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—GRM4—Parkinson's disease	0.00245	0.00287	CbGpPWpGaD
Dimetindene—Promethazine—DRD2—Parkinson's disease	0.00243	0.0165	CrCbGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—MAOA—Parkinson's disease	0.00243	0.00285	CbGpPWpGaD
Dimetindene—CHRM2—G alpha (i) signalling events—HTR1A—Parkinson's disease	0.00241	0.00282	CbGpPWpGaD
Dimetindene—Doxepin—DRD2—Parkinson's disease	0.00241	0.0164	CrCbGaD
Dimetindene—HRH1—GPCR ligand binding—PENK—Parkinson's disease	0.00236	0.00277	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—BDNF—Parkinson's disease	0.00234	0.00275	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—PENK—Parkinson's disease	0.00232	0.00273	CbGpPWpGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRBK1—Parkinson's disease	0.0023	0.00269	CbGpPWpGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	0.00227	0.00266	CbGpPWpGaD
Dimetindene—Orphenadrine—CYP2E1—Parkinson's disease	0.00226	0.0154	CrCbGaD
Dimetindene—CHRM2—G alpha (i) signalling events—DRD3—Parkinson's disease	0.00225	0.00264	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.00224	0.00263	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	0.00224	0.00262	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.00221	0.00259	CbGpPWpGaD
Dimetindene—Imipramine—HTR1A—Parkinson's disease	0.00221	0.015	CrCbGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	0.00221	0.00259	CbGpPWpGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	0.0022	0.00258	CbGpPWpGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.00219	0.00257	CbGpPWpGaD
Dimetindene—Amitriptyline—HTR1A—Parkinson's disease	0.00219	0.0149	CrCbGaD
Dimetindene—HRH1—GPCR ligand binding—PDYN—Parkinson's disease	0.00216	0.00253	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.00216	0.00253	CbGpPWpGaD
Dimetindene—Promazine—DRD2—Parkinson's disease	0.00214	0.0146	CrCbGaD
Dimetindene—CHRM2—GPCR ligand binding—PDYN—Parkinson's disease	0.00213	0.00249	CbGpPWpGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.00212	0.00249	CbGpPWpGaD
Dimetindene—Clomipramine—HTR2A—Parkinson's disease	0.00212	0.0144	CrCbGaD
Dimetindene—Chlorprothixene—HTR2A—Parkinson's disease	0.00211	0.0144	CrCbGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.00209	0.00245	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—NGF—Parkinson's disease	0.00208	0.00244	CbGpPWpGaD
Dimetindene—Nortriptyline—HTR2A—Parkinson's disease	0.00207	0.0141	CrCbGaD
Dimetindene—HRH1—GPCR downstream signaling—DGKQ—Parkinson's disease	0.00207	0.00243	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—DGKQ—Parkinson's disease	0.00204	0.00239	CbGpPWpGaD
Dimetindene—CHRM2—G alpha (i) signalling events—DRD2—Parkinson's disease	0.00204	0.00239	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—GRM5—Parkinson's disease	0.00201	0.00236	CbGpPWpGaD
Dimetindene—HRH1—G alpha (q) signalling events—EDN1—Parkinson's disease	0.00199	0.00233	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—HTR2A—Parkinson's disease	0.00198	0.00232	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—GRM5—Parkinson's disease	0.00198	0.00232	CbGpPWpGaD
Dimetindene—Trimipramine—HTR2A—Parkinson's disease	0.00195	0.0133	CrCbGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.00195	0.00228	CbGpPWpGaD
Dimetindene—Clomipramine—CYP2D6—Parkinson's disease	0.00194	0.0132	CrCbGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.00192	0.00225	CbGpPWpGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.00192	0.00225	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00192	0.00225	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.00192	0.00225	CbGpPWpGaD
Dimetindene—Nortriptyline—CYP2D6—Parkinson's disease	0.0019	0.0129	CrCbGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.00189	0.00222	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.00189	0.00222	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00189	0.00221	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—GPR37—Parkinson's disease	0.00188	0.00221	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—DGKQ—Parkinson's disease	0.00188	0.00221	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.00188	0.0022	CbGpPWpGaD
Dimetindene—Promethazine—HTR2A—Parkinson's disease	0.00188	0.0128	CrCbGaD
Dimetindene—Imipramine—DRD2—Parkinson's disease	0.00187	0.0127	CrCbGaD
Dimetindene—Amitriptyline—DRD2—Parkinson's disease	0.00186	0.0127	CrCbGaD
Dimetindene—Doxepin—HTR2A—Parkinson's disease	0.00186	0.0127	CrCbGaD
Dimetindene—CHRM2—Signaling by GPCR—DGKQ—Parkinson's disease	0.00185	0.00217	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—GPR37—Parkinson's disease	0.00185	0.00217	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.00185	0.00217	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.00182	0.00213	CbGpPWpGaD
Dimetindene—Imipramine—CYP2E1—Parkinson's disease	0.0018	0.0123	CrCbGaD
Dimetindene—Amitriptyline—CYP2E1—Parkinson's disease	0.00179	0.0122	CrCbGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.00179	0.0021	CbGpPWpGaD
Dimetindene—Trimipramine—CYP2D6—Parkinson's disease	0.00178	0.0121	CrCbGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—Parkinson's disease	0.00178	0.00209	CbGpPWpGaD
Dimetindene—Diphenhydramine—CYP2D6—Parkinson's disease	0.00175	0.0119	CrCbGaD
Dimetindene—HRH1—G alpha (q) signalling events—HTR2A—Parkinson's disease	0.00174	0.00204	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.00172	0.00202	CbGpPWpGaD
Dimetindene—Promethazine—CYP2D6—Parkinson's disease	0.00172	0.0117	CrCbGaD
Dimetindene—HRH1—GPCR ligand binding—ADORA2A—Parkinson's disease	0.00171	0.002	CbGpPWpGaD
Dimetindene—Doxepin—CYP2D6—Parkinson's disease	0.0017	0.0116	CrCbGaD
Dimetindene—CHRM2—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.00169	0.00199	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—ADORA2A—Parkinson's disease	0.00168	0.00197	CbGpPWpGaD
Dimetindene—Promazine—HTR2A—Parkinson's disease	0.00165	0.0112	CrCbGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.00165	0.00193	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.00165	0.00193	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.00162	0.0019	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.00162	0.0019	CbGpPWpGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—TNF—Parkinson's disease	0.0016	0.00188	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—GRK5—Parkinson's disease	0.00157	0.00184	CbGpPWpGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Parkinson's disease	0.00156	0.00183	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—GRK5—Parkinson's disease	0.00155	0.00181	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—HTR1A—Parkinson's disease	0.00148	0.00174	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—TAC1—Parkinson's disease	0.00146	0.00171	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—HTR1A—Parkinson's disease	0.00146	0.00171	CbGpPWpGaD
Dimetindene—Imipramine—HTR2A—Parkinson's disease	0.00145	0.00984	CrCbGaD
Dimetindene—Amitriptyline—HTR2A—Parkinson's disease	0.00144	0.00978	CrCbGaD
Dimetindene—CHRM2—GPCR ligand binding—TAC1—Parkinson's disease	0.00144	0.00168	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—DRD1—Parkinson's disease	0.00143	0.00168	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—GRK5—Parkinson's disease	0.00143	0.00167	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—DRD1—Parkinson's disease	0.00141	0.00165	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—GRM4—Parkinson's disease	0.00141	0.00165	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—GRK5—Parkinson's disease	0.0014	0.00164	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—DRD3—Parkinson's disease	0.00139	0.00163	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—GRM4—Parkinson's disease	0.00139	0.00162	CbGpPWpGaD
Dimetindene—Clomipramine—ABCB1—Parkinson's disease	0.00138	0.00942	CrCbGaD
Dimetindene—Chlorprothixene—ABCB1—Parkinson's disease	0.00138	0.00938	CrCbGaD
Dimetindene—CHRM2—GPCR ligand binding—DRD3—Parkinson's disease	0.00136	0.0016	CbGpPWpGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.00135	0.00158	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—VPS35—Parkinson's disease	0.00134	0.00157	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—PENK—Parkinson's disease	0.00134	0.00157	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.00132	0.00155	CbGpPWpGaD
Dimetindene—Imipramine—CYP2D6—Parkinson's disease	0.00132	0.009	CrCbGaD
Dimetindene—CHRM2—Signaling Pathways—VPS35—Parkinson's disease	0.00132	0.00155	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.00132	0.00155	CbGpPWpGaD
Dimetindene—Amitriptyline—CYP2D6—Parkinson's disease	0.00132	0.00895	CrCbGaD
Dimetindene—CHRM2—GPCR downstream signaling—PENK—Parkinson's disease	0.00131	0.00154	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.0013	0.00152	CbGpPWpGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—IL6—Parkinson's disease	0.00129	0.00151	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—GRM4—Parkinson's disease	0.00128	0.0015	CbGpPWpGaD
Dimetindene—Trimipramine—ABCB1—Parkinson's disease	0.00127	0.00867	CrCbGaD
Dimetindene—CHRM2—Signaling by GPCR—GRM4—Parkinson's disease	0.00126	0.00148	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—DRD2—Parkinson's disease	0.00125	0.00147	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—HTR7—Parkinson's disease	0.00125	0.00147	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—HTR7—Parkinson's disease	0.00123	0.00145	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—DRD2—Parkinson's disease	0.00123	0.00145	CbGpPWpGaD
Dimetindene—Promethazine—ABCB1—Parkinson's disease	0.00123	0.00835	CrCbGaD
Dimetindene—HRH1—GPCR downstream signaling—PDYN—Parkinson's disease	0.00122	0.00143	CbGpPWpGaD
Dimetindene—Doxepin—ABCB1—Parkinson's disease	0.00121	0.00826	CrCbGaD
Dimetindene—HRH1—Signaling by GPCR—PENK—Parkinson's disease	0.00121	0.00142	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—PDYN—Parkinson's disease	0.0012	0.00141	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—PENK—Parkinson's disease	0.00119	0.0014	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	0.00117	0.00138	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	0.00117	0.00137	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.00115	0.00135	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—GRM5—Parkinson's disease	0.00114	0.00133	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	0.00113	0.00133	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—GRM5—Parkinson's disease	0.00112	0.00131	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GPR37—Parkinson's disease	0.00111	0.0013	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—DGKQ—Parkinson's disease	0.00111	0.0013	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—PDYN—Parkinson's disease	0.00111	0.0013	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—DGKQ—Parkinson's disease	0.00109	0.00128	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GPR37—Parkinson's disease	0.00109	0.00128	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—PDYN—Parkinson's disease	0.00109	0.00128	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—GRM5—Parkinson's disease	0.00103	0.00121	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PPP1R1B—Parkinson's disease	0.00102	0.00119	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—GRM5—Parkinson's disease	0.00101	0.00119	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—EDN1—Parkinson's disease	0.001	0.00118	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PPP1R1B—Parkinson's disease	0.001	0.00117	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—EDN1—Parkinson's disease	0.000988	0.00116	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.000965	0.00113	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—ADORA2A—Parkinson's disease	0.00095	0.00111	CbGpPWpGaD
Dimetindene—Imipramine—ABCB1—Parkinson's disease	0.000945	0.00643	CrCbGaD
Dimetindene—Amitriptyline—ABCB1—Parkinson's disease	0.000939	0.00639	CrCbGaD
Dimetindene—HRH1—Signaling Pathways—RIT2—Parkinson's disease	0.000889	0.00104	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—HTR2A—Parkinson's disease	0.000878	0.00103	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—ADORA2A—Parkinson's disease	0.000877	0.00103	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—RIT2—Parkinson's disease	0.000874	0.00102	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—HTR2A—Parkinson's disease	0.000864	0.00101	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—ADORA2A—Parkinson's disease	0.000863	0.00101	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—TNF—Parkinson's disease	0.000852	0.000998	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GRK5—Parkinson's disease	0.000842	0.000987	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—HTR1A—Parkinson's disease	0.000838	0.000982	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GRK5—Parkinson's disease	0.000829	0.000972	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—TAC1—Parkinson's disease	0.000825	0.000967	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—HTR1A—Parkinson's disease	0.000824	0.000966	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—TAC1—Parkinson's disease	0.000812	0.000951	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—DRD1—Parkinson's disease	0.000809	0.000948	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—DRD1—Parkinson's disease	0.000796	0.000933	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—DRD3—Parkinson's disease	0.000783	0.000918	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—DRD3—Parkinson's disease	0.000771	0.000904	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—HTR1A—Parkinson's disease	0.000761	0.000892	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GRM4—Parkinson's disease	0.000756	0.000886	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—TAC1—Parkinson's disease	0.000749	0.000878	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—HTR1A—Parkinson's disease	0.000748	0.000877	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GRM4—Parkinson's disease	0.000743	0.000872	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—TAC1—Parkinson's disease	0.000737	0.000864	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—DRD1—Parkinson's disease	0.000735	0.000861	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—ADRBK1—Parkinson's disease	0.000732	0.000858	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—DRD1—Parkinson's disease	0.000723	0.000847	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—ADRBK1—Parkinson's disease	0.00072	0.000844	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—MAG—Parkinson's disease	0.000716	0.00084	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PENK—Parkinson's disease	0.000716	0.00084	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—DRD3—Parkinson's disease	0.000711	0.000834	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—HTR7—Parkinson's disease	0.000708	0.000831	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—DRD2—Parkinson's disease	0.000708	0.000831	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PENK—Parkinson's disease	0.000705	0.000826	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—MAG—Parkinson's disease	0.000705	0.000826	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—DRD3—Parkinson's disease	0.0007	0.000821	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—HTR7—Parkinson's disease	0.000697	0.000817	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—DRD2—Parkinson's disease	0.000697	0.000817	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—IL6—Parkinson's disease	0.000687	0.000806	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—ADRBK1—Parkinson's disease	0.000664	0.000779	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PDYN—Parkinson's disease	0.000655	0.000768	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—ADRBK1—Parkinson's disease	0.000654	0.000766	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PDYN—Parkinson's disease	0.000645	0.000756	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—HTR7—Parkinson's disease	0.000643	0.000754	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—DRD2—Parkinson's disease	0.000643	0.000754	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—HTR7—Parkinson's disease	0.000633	0.000742	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—DRD2—Parkinson's disease	0.000633	0.000742	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GFAP—Parkinson's disease	0.000616	0.000722	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GRM5—Parkinson's disease	0.000609	0.000714	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GFAP—Parkinson's disease	0.000606	0.00071	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GRM5—Parkinson's disease	0.000599	0.000702	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—EDN1—Parkinson's disease	0.000567	0.000665	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—EDN1—Parkinson's disease	0.000558	0.000654	CbGpPWpGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	0.00054	0.000634	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—FGF20—Parkinson's disease	0.000534	0.000626	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—FGF20—Parkinson's disease	0.000525	0.000616	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ADORA2A—Parkinson's disease	0.000518	0.000607	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—EDN1—Parkinson's disease	0.000515	0.000604	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ADORA2A—Parkinson's disease	0.00051	0.000597	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—EDN1—Parkinson's disease	0.000507	0.000594	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—HTR2A—Parkinson's disease	0.000496	0.000582	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—HTR2A—Parkinson's disease	0.000488	0.000572	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—INSR—Parkinson's disease	0.000478	0.00056	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—INSR—Parkinson's disease	0.00047	0.000551	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—FGB—Parkinson's disease	0.000452	0.000529	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—HTR2A—Parkinson's disease	0.000451	0.000528	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—HTR1A—Parkinson's disease	0.000449	0.000527	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—FGB—Parkinson's disease	0.000444	0.000521	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—HTR2A—Parkinson's disease	0.000443	0.00052	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—TAC1—Parkinson's disease	0.000442	0.000519	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—HTR1A—Parkinson's disease	0.000442	0.000518	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—TAC1—Parkinson's disease	0.000435	0.00051	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—DRD1—Parkinson's disease	0.000434	0.000509	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—DRD1—Parkinson's disease	0.000427	0.000501	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—DRD3—Parkinson's disease	0.00042	0.000493	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—DRD3—Parkinson's disease	0.000414	0.000485	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ADRBK1—Parkinson's disease	0.000392	0.00046	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ADRBK1—Parkinson's disease	0.000386	0.000453	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—HTR7—Parkinson's disease	0.00038	0.000446	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—DRD2—Parkinson's disease	0.00038	0.000446	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—DRD2—Parkinson's disease	0.000374	0.000438	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—HTR7—Parkinson's disease	0.000374	0.000438	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—IGF2—Parkinson's disease	0.000318	0.000373	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—IGF2—Parkinson's disease	0.000313	0.000367	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—IGF1R—Parkinson's disease	0.000308	0.000361	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—EDN1—Parkinson's disease	0.000304	0.000357	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—IGF1R—Parkinson's disease	0.000303	0.000355	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—EDN1—Parkinson's disease	0.000299	0.000351	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—NGF—Parkinson's disease	0.00028	0.000328	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—NGF—Parkinson's disease	0.000275	0.000323	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—HTR2A—Parkinson's disease	0.000266	0.000312	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—HTR2A—Parkinson's disease	0.000262	0.000307	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—APOE—Parkinson's disease	0.000247	0.00029	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—APOE—Parkinson's disease	0.000244	0.000285	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—INS—Parkinson's disease	0.000211	0.000248	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—INS—Parkinson's disease	0.000208	0.000244	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—CASP3—Parkinson's disease	0.000157	0.000185	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—IL6—Parkinson's disease	0.000156	0.000183	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—CASP3—Parkinson's disease	0.000155	0.000182	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—IL6—Parkinson's disease	0.000154	0.00018	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—MAPK8—Parkinson's disease	0.000145	0.00017	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—MAPK8—Parkinson's disease	0.000142	0.000167	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—IL6—Parkinson's disease	9.24e-05	0.000108	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—IL6—Parkinson's disease	9.09e-05	0.000107	CbGpPWpGaD
